
Sunday, April 17, 2022 11:58:23 AM

Liked By
Spread the love. Be the first to like this post!
Recent ABBV News
- Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023 • PR Newswire (US) • 01/25/2023 04:42:00 PM
- JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE • PR Newswire (US) • 01/18/2023 01:00:00 PM
- SkinMedica® Launches Even & Correct • PR Newswire (US) • 01/17/2023 01:00:00 PM
- Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields • GlobeNewswire Inc. • 01/16/2023 02:00:00 PM
- AbbVie, Anima Biotech to Collaborate on mRNA Biology Modulators • Dow Jones News • 01/10/2023 01:50:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/10/2023 01:16:51 PM
- AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets • PR Newswire (US) • 01/10/2023 01:00:00 PM
- QULIPTA(MC) est maintenant approuvé par Santé Canada pour la prévention de la migraine épisodique chez les adultes • PR Newswire (Canada) • 01/09/2023 12:01:00 PM
- QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults • PR Newswire (Canada) • 01/09/2023 12:01:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 09:16:41 PM
- AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets • Business Wire • 01/06/2023 01:00:00 PM
- AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets • PR Newswire (US) • 01/06/2023 01:00:00 PM
- AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call • PR Newswire (US) • 01/05/2023 01:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/03/2023 10:07:20 PM
- AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/03/2023 01:00:00 PM
- U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder • PR Newswire (US) • 12/16/2022 11:39:00 PM
- AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age • PR Newswire (US) • 12/16/2022 12:30:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 10:06:53 PM
- AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year • PR Newswire (US) • 12/12/2022 05:59:00 PM
- AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas • PR Newswire (US) • 12/11/2022 10:30:00 PM
- AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients • PR Newswire (US) • 12/10/2022 08:00:00 PM
- AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science • PR Newswire (US) • 12/10/2022 04:15:00 PM
- AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline • PR Newswire (US) • 12/06/2022 01:00:00 PM
- AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress • PR Newswire (US) • 12/06/2022 07:00:00 AM
- AbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan • PR Newswire (Canada) • 12/01/2022 12:01:00 PM
1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition • CBDW • Jan 27, 2023 11:59 AM
IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 • IQST • Jan 26, 2023 9:53 AM
Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements • ARWYF • Jan 26, 2023 8:46 AM
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 • UCASU • Jan 26, 2023 7:21 AM
Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market • KAYS • Jan 25, 2023 10:53 AM
B2 Digital's B2 SPORTS NETWORK (B2SN) Expands Distribution to Europe, Russia, and Asia with StayLIVE Agreement • BTDG • Jan 25, 2023 10:00 AM